Oral amiodarone therapy in dogs with atrial fibrillation

Journal of Veterinary Internal Medicine

Volumn 20, Issue 4, 2006, Pages 921-926

  Saunders, Ashley B ^a   Miller, Matthew W ^a   Gordon, Sonya G ^a   Van De Wiele, Carrie M ^a,b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Arrhythmia; Cardiomyopathy; Congestive heart failure

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT;

ANIMAL; ANIMAL DISEASE; DOG; DOG DISEASE; FEMALE; HEART ATRIUM FIBRILLATION; MALE; REVIEW;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOG DISEASES; DOGS; FEMALE; MALE;

CANIS FAMILIARIS;

EID: 33748337510     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2006)20[921:OATIDW]2.0.CO;2     Document Type: Review

References (48)

1. Patterson DF, Detweiler DK, Hubben K, et al. Spontaneous abnormal cardiac arrhythmias and conduction disturbances in the dog. Am J Vet Res 1961;22:355-369.
2. Guglielmini C, Chetboul V, Pietra M, et al. Influence of left atrial enlargement and body weight on the development of atrial fibrillation: Retrospective study in 205 dogs. Vet J 2000;160: 235-241.
3. Bonagura JD, Ware WA. Atrial fibrillation in the dog: Clinical findings in 81 cases. J Am Anim Hosp Assoc 1986; 22:111-120.
4. Falk RH. Atrial fibrillation. N Engl J Med 2001;344: 1067-1078.
5. Morley J, Marinchak R, Rials SJ, et al. Atrial fibrillation, anticoagulation, and stroke. Am J Cardiol 1996;77:38A-44A.
6. Jalife J. Experimental and clinical AF mechanisms: Bridging the divide. J Interv Card Electrophysiol 2003;9:85-92.
7. Veenhuyzen GD, Simpson CS, Abdollah H. Atrial fibrillation. Can Med Assoc J 2004;171:755-760.
8. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659-666.
9. Saxonhouse SJ, Curtis AB. Risks and benefits of rate control versus maintenance of sinus rhythm. Am J Cardiol 2003;91: 27D-32D.
10. The AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
11. Gronefeld GC, Lilienthal J, Kuck KH, et al. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Eur Heart J 2003;24:1430-1436.
12. Al-Khatib SM, Shaw LK, Lee KL, et al. Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure? Am J Cardiol 2004;94:797-800.
13. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological intervention in atrial fibrillation (PIAF): A randomised trial. Lancet 2000;356: 1789-1794.
14. Madrid AH, Escobar C, Rebollo JMG, et al. Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: Results of the irebesartan-amdiodarone trial. Card Electrophysiol Rev 2003;7:243-246.
15. Joglar JA, Kowal RC. Electrical cardioversion of atrial fibrillation. Cardiol Clin 2004;22:101-111.
16. Jais P, Shah DC, Haissaguerre M, et al. Catheter ablation for atrial fibrillation. Annu Rev Med 2000;51:431-441.
17. Cooper JM, Katcher MS, Orlov MV. Implantable devices for the treatment of atrial fibrillation. N Engl J Med 2002; 346:2062-2068.
18. Cox JL, Boineau JP, Schuessler RB, et al. Five-year experience with the maze procedure for atrial fibrillation. Ann Thorac Surg 1993;56:814-823.
19. Ettinger S. Conversion of spontaneous atrial fibrillation in dogs, using direct current synchronized shock. J Am Vet Med Assoc 1968;152:41-46.
20. Calvert CA, Sammarco C, Pickus C. Positive Coombs' test results in two dogs treated with amiodarone. J Am Vet Med Assoc 2000;216:1933-1936.
21. Johnson JT. Conversion of atrial fibrillation in two dogs using verapamil and supportive therapy. J Am Anim Hosp Assoc 1984;21:429-434.
22. Pyle RL. Conversion of atrial fibrillation with quinidine sulfate in a dog. J Am Vet Med Assoc 1967;151:582-589.
23. Bonagura JD. Atrial arrhythmias. In: Kirk RW, ed. Current Veterinary Therapy X. Philadelphia, PA: WB Saunders Co; 1989:271-278.
24. Crystal MA, Rush JE. ECG of the Month. J Am Vet Med Assoc 1991;199:48-50.
25. Hogan DF, Sisson DD, McVey AS. ECG of the Month. J Am Vet Med Assoc 1998;213:610-611.
26. Hamer AW, Mandel WJ, Zaher CA, et al. The electrophysiologic basis for the use of amiodarone for treatment of cardiac arrhythmias. Pacing Clin Electrophysiol 1983;6:784-794.
27. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999;100:2025-2034.
28. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation 1999;98:2574-2579.
29. Vora A, Karnad D, Goyal V, et al. Control of rate versus rhythm in rheumatic atrial fibrillation: A randomized study. Ind Heart J 2004;56:110-116.
30. Kumana CR, Cheung BM, Cheung GT, et al. Rhythm vs. rate control of atrial fibrillation meta-analysed by number needed to treat. Br J Clin Pharmacol 2005;60:347-354.
31. Weinfeld MS, Drazner MH, Stevenson WG, et al. Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure. J Heart Lung Transplant 2000;19:638-643.
32. Bicer S, Nakayama T, Hamlin RL. Effects of chronic oral amiodarone on left ventricular function, ECGs, serum chemistries, and exercise tolerance in healthy dogs. J Vet Intern Med 2002; 16:247-254.
33. Hohnloser SH. Proarrhythmia with class III antiarrhythmic drugs: Types, risks, and management. Am J Cardiol 1997;80(8A): 82G-89G.
34. Middlekauff HR, Stevenson WG, Saxon LA, et al. Amiodarone and torsades de pointes in patients with advanced heart disease. Am J Cardiol 1995;76:499-502.
35. Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: A meta-analysis. J Am Coll Cardiol 1997;30:791-798.
36. Jacobs G, Calvert C, Kraus M. Hepatopathy in 4 dogs treated with amiodarone. J Vet Intern Med 2000;14:96-99.
37. Bicer S, Fuller GA, Wilkie DA, et al. Amiodarone-induced keratopathy in healthy dogs. Vet Ophthalmol 2002;5:35-38.
38. Burns KE, Piliotis E, Garcia BM, et al. Amiodarone pulmonary, neuromuscular and ophthalmological toxicity. Can Respir J 2000;7:193-197.
39. Harris L, McKenna WJ, Rowland E. Side effects and possible contraindications of amiodarone use. Am Heart J 1983; 106:916-923.
40. Brien JF, Jimmo S, Brennan FJ, et al. Disposition of amiodarone and its proximate metabolite, desethylamiodarone, in the dog for oral administration of single-dose and short-term drug regimens. Drug Metab Dispos 1990;18:846-851.
41. Latini R, Connolly SJ, Kates RE. Myocardial disposition of amiodarone in the dog. J Pharmacol Exp Ther 1983;224:603-608.
42. Pollack PT, You YD. Monitoring of hepatic function during amiodarone therapy. Am J Cardiol 2003;91:613-616.
43. Pollack PT, Shafer SL. Use of population modeling to define rational monitoring of amiodarone hepatic effects. Clin Pharmacol Ther 2004;75:342-351.
44. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989;9:679-685.
45. Calvert CA, Pickus CW, Jacobs GJ, et al. Signalment, survival, and prognostic factors in Doberman Pinschers with end-stage cardiomyopathy. J Vet Intern Med 1997;11: 323-326.
46. Umana E, Solares CA, Alpert MA. Tachycardia-induced cardiomyopathy. Am J Med 2003;114:51-55.
47. Uechi M, Shimizu A, Mizuno M. Heart rate modulation by sympathetic nerves in dogs with heart failure. J Vet Med Sci 2002;64:1023-1029.
48. Rossen RM, Alderman EL, Harrison DC. Circulatory response to vasodilator therapy in congestive cardiomyopathy. Br Heart J 1976;38:695-700.